Analyst Price Targets — BMY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 5, 2026 1:40 pm | — | Roth Capital | $75.00 | $63.47 | TheFly | Best Buy downgraded, Bristol Myers upgraded: Wall Street's top analyst calls |
| August 5, 2026 11:53 am | Jasper Hellweg | Argus Research | $75.00 | $65.89 | TheFly | Bristol Myers upgraded to Buy from Hold at Argus |
| August 4, 2026 12:48 pm | Trung Huynh | RBC Capital | $64.00 | $64.73 | StreetInsider | RBC Capital on Bristol-Myers Squibb's (BMY) AZN Deal Feedback |
| July 31, 2026 12:26 pm | Carter Gould | Cantor Fitzgerald | $59.00 | $63.67 | TheFly | Bristol Myers price target raised to $59 from $54 at Cantor Fitzgerald |
| July 31, 2026 10:48 am | Seamus Fernandez | Guggenheim | $75.00 | $64.86 | TheFly | Bristol Myers price target raised to $75 from $72 at Guggenheim |
| July 31, 2026 10:13 am | — | Wells Fargo | $65.00 | $64.86 | TheFly | Bristol Myers price target raised to $65 from $60 at Wells Fargo |
| April 8, 2026 11:33 am | — | Cantor Fitzgerald | $54.00 | $59.20 | TheFly | Bristol Myers price target raised to $54 from $45 at Cantor Fitzgerald |
| March 6, 2026 12:44 pm | Michael Yee | UBS | $70.00 | $59.79 | StreetInsider | Bristol-Myers Squibb Co. (BMY) PT Raised to $70 at UBS Ahead of Major Catalyst |
| February 24, 2026 9:03 pm | Trung Huynh | RBC Capital | $60.00 | $61.60 | StreetInsider | RBC Capital Starts Bristol-Myers Squibb Co. (BMY) at Sector Perform |
| February 23, 2026 11:32 am | — | Piper Sandler | $75.00 | $60.66 | TheFly | Bristol Myers price target raised to $75 from $66 at Piper Sandler |
Latest News for BMY
Technical indicators have turned bullish for the three stocks.
If you're looking to invest $1,000 in a dividend stock, look to the pharmaceutical sector.
XLV bundles the entire healthcare sector into one tidy package, but its cap-weighted structure quietly siphons off the income that dividend investors came for. Three stocks already inside the fund tell a very different yield story.
[url="]Bristol Myers Squibb[/url] (NYSE: BMY) today presented results from the EXPLORER-LTE cohort of the MAVA-LTE study (NCT03723655) in a late-breaker present
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten).
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.